A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
A phase 1/2 trial of Adebrelimab, Pyrotinib and Trastuzumab rezetecan in non-small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05482568 by Jiangsu HengRui Medicine Co., Ltd., with 324 participants planned, started 2022-09-15 and due to reach its primary completion in 2026-12. Interventions recorded: SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316.
Similar pages
not linked directly; found by shared links- TrialA Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Shares Pyrotinib, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Shares Pyrotinib, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.